How to Define Significant Loss (When the DEA Won't) — Plus Building a Diversion Program Across a Health System

What exactly counts as a "significant loss" of controlled substances?It's one of the most common questions in diversion prevention—and one the DEA intentionally leaves unanswered. That ambiguity can make reporting decisions difficult, especially for large healthcare systems with multiple facilities.In this episode of Drug Diversion Insights, Terri is joined by Calvin Parmiter, System Pharmacy Manager for Diversion and Compliance at WVU Medicine, and Shannan Molnar, Drug Diversion Coordinator, to discuss how their team created a standardized process for defining significant loss and built a diversion prevention program that works across an entire health system.In this episode, we discuss:Why the DEA intentionally leaves "significant loss" undefinedHow WVU Medicine developed standardized reporting criteriaCreating a checklist that removes guesswork from reporting decisionsBuilding consistency across multiple hospitalsThe unique challenges of supporting rural and community facilitiesPreparing local leadership to respond effectively when diversion specialists aren't on siteLessons learned from implementing a system-wide diversion programPractical advice for organizations looking to improve consistency and strengthen complianceWhether you're a diversion specialist, pharmacy leader, compliance professional, medication safety officer, or healthcare executive, this conversation offers practical strategies for creating scalable, standardized diversion prevention processes that support both regulatory compliance and patient safety.Sometimes the most effective diversion programs aren't built around reacting to problems—they're built around creating consistent processes before problems occur.More from Rxpert Solutions